Molecular Profile | BRAF V600X |
Therapy | Trametinib + Dabrafenib |
Indication/Tumor Type | colorectal cancer |
Response Type | sensitive |
Create By | spatterson |
Update By | cms |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References | BRAF V600X | colorectal cancer | sensitive | Trametinib + Dabrafenib | Phase Ib/II | Actionable | In a Phase Ib/II trial, treatment with the combination of Mekinist (trametinib) and Tafinlar (dabrafenib) resulted in partial response or better in 12% (5/43), including 1 complete response, and stable disease in 51% (22/43) of patients with BRAF V600-mutant colorectal cancer (PMID: 26392102). | detail... 26392102 |
---|
PubMed Id | Reference Title | Details |
---|---|---|
Phase 1-2 trial of the BRAF inhibitor dabrafenib (D) plus MEK inhibitor trametinib (T) in BRAF V600 mutant colorectal cancer (CRC): Updated efficacy and biomarker analysis. | Full reference... | |
(26392102) | Combined BRAF and MEK Inhibition With Dabrafenib and Trametinib in BRAF V600-Mutant Colorectal Cancer. | Full reference... |